Skip to main content
Top
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Optimal interval of endoscopic screening based on stage distributions of detected gastric cancers

Authors: Chisato Hamashima, Rintaro Narisawa, Kazuei Ogoshi, Toshiyuki Kato, Kazutaka Fujita

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Although Korea and Japan have a national gastric cancer screening program, their screening intervals are different. The optimal screening interval of endoscopic screening in Japan was investigated based on the stage distributions of screen-detected gastric cancers.

Methods

Patients with gastric cancer detected by endoscopic and radiographic screenings were selected from the Niigata City Medical Association database. The stage distributions of the detected gastric cancers were compared among patients with different screening histories in both groups. Gastric cancer specific survival rates were analyzed using the Kaplan-Meier method with the log-rank test.

Results

There were 1585 and 462 subjects in the endoscopic and radiographic screening groups, respectively. In the endoscopic screening group, the stage IV proportion was lower in patients with screening history 1 and 2 years before diagnosis than in patients without screening history. Stage IV development was significantly related to the absence of screening history (p < 0.001); however, there were no differences between patients who had endoscopic screening history 2 and 3 years before diagnosis. The survival rates were not significantly different between patients with endoscopic screening 1 and 2 years previously (p = 0.7763). The survival rates were significantly higher in patients with endoscopic screening history 1 and 2 years before diagnosis than in patients without screening history (p < 0.001), and in patients with endoscopic screaming 3 years before diagnosis (P < 0.0069).

Conclusion

The endoscopic screening interval for gastric cancer can be expanded to at least 2 years based on the stage distributions of detected cancers and the patient survival rates.
Literature
1.
go back to reference International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. WHO. 2012. http://globocan.iarc.fr/. Accessed 10 Jan 2017. International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. WHO. 2012. http://​globocan.​iarc.​fr/​. Accessed 10 Jan 2017.
2.
go back to reference Leung WK, Wu MS, Kakugawa Y, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 2008;9:279–87.CrossRefPubMed Leung WK, Wu MS, Kakugawa Y, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 2008;9:279–87.CrossRefPubMed
3.
go back to reference Kim Y, Jun JK, Choi KS, et al. Overview of the national cancer screening programme and the cancer screening status in Korea. Asian Pac J Cancer Prev. 2011;12:725–30.PubMed Kim Y, Jun JK, Choi KS, et al. Overview of the national cancer screening programme and the cancer screening status in Korea. Asian Pac J Cancer Prev. 2011;12:725–30.PubMed
4.
go back to reference Hamashima C, Fukao A. Quality assurance manual of endoscopic screening for gastric cancer in Japanese communities. Jpn J Clin Oncol. 2016;46:1053–61.CrossRef Hamashima C, Fukao A. Quality assurance manual of endoscopic screening for gastric cancer in Japanese communities. Jpn J Clin Oncol. 2016;46:1053–61.CrossRef
6.
go back to reference International Agency for Research on Cancer, WHO. IARC handbooks on cancer prevention volume 10: cervical cancer screening. Lyon: IARC Press; 2005. p. 180–3. International Agency for Research on Cancer, WHO. IARC handbooks on cancer prevention volume 10: cervical cancer screening. Lyon: IARC Press; 2005. p. 180–3.
7.
go back to reference Park HA, Nam SY, Lee SK, et al. The Korean guideline for gastric cancer screening. J Korean Med Assoc. 2015;58:373–84.CrossRef Park HA, Nam SY, Lee SK, et al. The Korean guideline for gastric cancer screening. J Korean Med Assoc. 2015;58:373–84.CrossRef
8.
go back to reference Promotion of evidence based cancer screening. National Cancer Center, Japan. The Japanese guidelines for gastric cancer screening 2015. Tokyo: National Cancer Center; 2017. http://canscreen.ncc.go.jp/. Accessed 15 Feb 2017 Promotion of evidence based cancer screening. National Cancer Center, Japan. The Japanese guidelines for gastric cancer screening 2015. Tokyo: National Cancer Center; 2017. http://​canscreen.​ncc.​go.​jp/​. Accessed 15 Feb 2017
9.
go back to reference Hamashima C, Goto R. Potential capacity of endoscopic screening for gastric cancer in Japan. Cancer Sci. 2017;108:101–7.CrossRefPubMed Hamashima C, Goto R. Potential capacity of endoscopic screening for gastric cancer in Japan. Cancer Sci. 2017;108:101–7.CrossRefPubMed
10.
go back to reference Tashiro A, Sano M, Kinameri K, et al. Comparing mass screening techniques for gastric cancer in Japan. World J Gastroenterol. 2006;12:4873–4.PubMedPubMedCentral Tashiro A, Sano M, Kinameri K, et al. Comparing mass screening techniques for gastric cancer in Japan. World J Gastroenterol. 2006;12:4873–4.PubMedPubMedCentral
11.
go back to reference Ogoshi K, Narisawa R, Kato T, et al. Endoscopic screening for gastric cancer in Niigata city. Jpn J Endosc Forum Dig Dis. 2010;26:5–16. Ogoshi K, Narisawa R, Kato T, et al. Endoscopic screening for gastric cancer in Niigata city. Jpn J Endosc Forum Dig Dis. 2010;26:5–16.
12.
go back to reference Oshima A. A critical review of cancer screening programs in Japan. Int J Technol Assess Health Care. 1994;10:346–58.CrossRefPubMed Oshima A. A critical review of cancer screening programs in Japan. Int J Technol Assess Health Care. 1994;10:346–58.CrossRefPubMed
13.
go back to reference Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 3rd English edition. Gastric Cancer. 2011;14:101–12.CrossRef Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 3rd English edition. Gastric Cancer. 2011;14:101–12.CrossRef
14.
go back to reference Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.CrossRefPubMed Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.CrossRefPubMed
16.
go back to reference Jun JK, Choi KS, Lee HY, et al. Effectiveness of the Korean National Cancer Screening Program in reducing gastric cancer mortality. Gastroenterol. 2017;152(6):1319–28. [Epub ahead of print]CrossRef Jun JK, Choi KS, Lee HY, et al. Effectiveness of the Korean National Cancer Screening Program in reducing gastric cancer mortality. Gastroenterol. 2017;152(6):1319–28. [Epub ahead of print]CrossRef
17.
go back to reference Chen Q, Yu L, Hao CQ, et al. Effectiveness of endoscopic gastric cancer screening in a rural area of Linzhou, China: results from a case-control study. Cancer Med. 2016;5:2615–22.CrossRefPubMedPubMedCentral Chen Q, Yu L, Hao CQ, et al. Effectiveness of endoscopic gastric cancer screening in a rural area of Linzhou, China: results from a case-control study. Cancer Med. 2016;5:2615–22.CrossRefPubMedPubMedCentral
18.
go back to reference Hamashima C, Shabana M, Okada K, et al. Mortality reduction from gastric cancer by endoscopic and radiographic screening. Cancer Sci. 2015;106:1744–9.CrossRefPubMedPubMedCentral Hamashima C, Shabana M, Okada K, et al. Mortality reduction from gastric cancer by endoscopic and radiographic screening. Cancer Sci. 2015;106:1744–9.CrossRefPubMedPubMedCentral
19.
go back to reference Nam JH, Choi IJ, Cho SJ, et al. Association of the interval between endoscopies with gastric cancer stage at diagnosis in a region of high prevalence. Cancer. 2012;118:4953–60.CrossRefPubMed Nam JH, Choi IJ, Cho SJ, et al. Association of the interval between endoscopies with gastric cancer stage at diagnosis in a region of high prevalence. Cancer. 2012;118:4953–60.CrossRefPubMed
20.
go back to reference Park CH, Kim EH, Chung H, et al. The optimal endoscopic screening interval for detecting early gastric neoplasms. Gastrointest Endosc. 2014;80:253–9.CrossRefPubMed Park CH, Kim EH, Chung H, et al. The optimal endoscopic screening interval for detecting early gastric neoplasms. Gastrointest Endosc. 2014;80:253–9.CrossRefPubMed
22.
go back to reference Lee TY, Wang RC, Lee YC, et al. The Incidence of gastric adenocarcinoma among patients with gastric intestinal metaplasia: A long-term cohort study. J Clin Gastroenterol. 2016;50:532–7.CrossRefPubMed Lee TY, Wang RC, Lee YC, et al. The Incidence of gastric adenocarcinoma among patients with gastric intestinal metaplasia: A long-term cohort study. J Clin Gastroenterol. 2016;50:532–7.CrossRefPubMed
23.
24.
go back to reference Yamada H, Ikegami M, Shimoda T, et al. Long-term follow-up study of gastric adenoma/dysplasia. Endoscopy. 2004;36:390–6.CrossRefPubMed Yamada H, Ikegami M, Shimoda T, et al. Long-term follow-up study of gastric adenoma/dysplasia. Endoscopy. 2004;36:390–6.CrossRefPubMed
25.
go back to reference Fujisaki J, Nakajima T, Hirasawa T, et al. Natural history of gastric cancer―a case followed up for eight years: early to advanced gastric cancer. Clin J Gastroenterol. 2012;5:351–4.CrossRefPubMedPubMedCentral Fujisaki J, Nakajima T, Hirasawa T, et al. Natural history of gastric cancer―a case followed up for eight years: early to advanced gastric cancer. Clin J Gastroenterol. 2012;5:351–4.CrossRefPubMedPubMedCentral
26.
go back to reference Furukawa K, Yamada K, Konomi K, et al. Gastric carcinoma resected 95 months after being diagnosed: report of a case. Surg Today. 1994;24:756–8.CrossRefPubMed Furukawa K, Yamada K, Konomi K, et al. Gastric carcinoma resected 95 months after being diagnosed: report of a case. Surg Today. 1994;24:756–8.CrossRefPubMed
28.
go back to reference Wilt TJ, Harris RP, Qaseem A. Screening for cancer: advice for high-value care from the American College of Physicians. Ann Intern Med. 2015;162:718–25.CrossRefPubMed Wilt TJ, Harris RP, Qaseem A. Screening for cancer: advice for high-value care from the American College of Physicians. Ann Intern Med. 2015;162:718–25.CrossRefPubMed
29.
go back to reference Harris RP, Wilt TJ, Qaseem A. A value framework for cancer screening: advice for high-value care from the American college of physicians. Ann Intern Med. 2015;162:712–7.CrossRefPubMed Harris RP, Wilt TJ, Qaseem A. A value framework for cancer screening: advice for high-value care from the American college of physicians. Ann Intern Med. 2015;162:712–7.CrossRefPubMed
30.
go back to reference IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. HELICOBACTER PYLORI. In: IARC working group reports volume 8. Helicobacter pylori eradication as a strategy for preventing gastric cancer. Lyon: IARC; 2014. p. 1–4. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. HELICOBACTER PYLORI. In: IARC working group reports volume 8. Helicobacter pylori eradication as a strategy for preventing gastric cancer. Lyon: IARC; 2014. p. 1–4.
31.
go back to reference Charvat H, Sasazuki S, Inoue M, et al. JPHC study group. Prediction of the 10-year probability of gastric cancer occurrence in the Japanese population: the JPHC study cohort II. Int J Cancer. 2016;138:320–31.CrossRefPubMed Charvat H, Sasazuki S, Inoue M, et al. JPHC study group. Prediction of the 10-year probability of gastric cancer occurrence in the Japanese population: the JPHC study cohort II. Int J Cancer. 2016;138:320–31.CrossRefPubMed
Metadata
Title
Optimal interval of endoscopic screening based on stage distributions of detected gastric cancers
Authors
Chisato Hamashima
Rintaro Narisawa
Kazuei Ogoshi
Toshiyuki Kato
Kazutaka Fujita
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3710-x

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine